{
  "clinical_study": {
    "title": "A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)",
    "nct_identifier": "NCT05036135",
    "indication": "Pulmonary Arterial Hypertension",
    "intervention": "AV-101, Placebo",
    "study_arms": {
      "intervention": 3,
      "placebo": 1
    },
    "number_of_participants": 202,
    "average_age": null,
    "age_range": [
      "18 Years",
      "75 Years"
    ],
    "interventional_drug": [
      {
        "name": "AV-101",
        "dose": null,
        "frequency": null,
        "formulation": "dry powder inhalation"
      },
      {
        "name": "Placebo",
        "dose": null,
        "frequency": null,
        "formulation": "dry powder inhalation"
      }
    ],
    "endpoints": [
      "Phase 2b: Change from Baseline in Pulmonary Vascular Resistance (PVR)",
      "Phase 3: Change from Baseline in Six Minute Walk Distance (6MWD)",
      "Phase 2b: Change from Baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP)",
      "Phase 2b: Change from Baseline in Six Minute Walk Distance (6MWD)",
      "Phase 2b: Time to Clinical Worsening",
      "Phase 2b: Proportion of Subjects with Improvement in WHO Functional Class",
      "Phase 2b: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score",
      "Phase 2b: Change from Baseline in Health-Related Quality of Life emPHasis-10 Questionnaire Score",
      "Phase 3: Change from Baseline in NT-proBNP",
      "Phase 3: Time to Clinical Worsening",
      "Phase 3: Proportion of Subjects with Improvement in WHO Functional Class",
      "Phase 3: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score",
      "Phase 3: Change from Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire Score"
    ],
    "baseline_characteristics": []
  },
  "endpoints": [
    {
      "name": "Phase 2b: Change from Baseline in Pulmonary Vascular Resistance (PVR)",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 3: Change from Baseline in Six Minute Walk Distance (6MWD)",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 2b: Change from Baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP)",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 2b: Change from Baseline in Six Minute Walk Distance (6MWD)",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 2b: Time to Clinical Worsening",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 2b: Proportion of Subjects with Improvement in WHO Functional Class",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 2b: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score",
      "description": "REVEAL Lite 2.0 risk scores range from 1 to 14; a higher score represents higher risk",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 2b: Change from Baseline in Health-Related Quality of Life emPHasis-10 Questionnaire Score",
      "description": "emPHasis-10 questionnaire scores range from 0 - 50; a higher score represents a higher symptom burden",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 3: Change from Baseline in NT-proBNP",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 3: Time to Clinical Worsening",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 3: Proportion of Subjects with Improvement in WHO Functional Class",
      "description": "",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 3: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score",
      "description": "REVEAL Lite 2.0 risk scores range from 1 to 14; a higher score represents higher risk",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Phase 3: Change from Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire Score",
      "description": "PAH-SYMPACT is a patient reported outcome instrument developed to assess PAH symptoms and impacts",
      "timepoint": "24 weeks",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    }
  ],
  "baseline_measures": []
}